Market Access Unlocking oncology access: What the OECD findings mean for m... New policies are shaping the market access landscape, such as the introduction of the EU HTA for oncology medicines.
R&D No longer the little fish: How Europe is holding its own thr... It goes without saying that we are living in uncertain times, yet, this holds particularly true for the pharmaceutical industry.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.